← All trials
NCT06069856
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Oct 6, 2023
- Last posted
- Oct 6, 2023
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- George Washington UniversityLead sponsor
- Africa Academy for Public HealthCollaborator
- Columbia UniversityCollaborator
- Columbia UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Ifakara Health InstituteCollaborator
- Ifakara Health InstituteOverall official - principal investigator
- Muhimbili UniversityCollaborator
- Muhimbili UniversityOverall official - principal investigator
- George Washington UniversityOverall official - principal investigator
- George Washington UniversitySponsor investigator
- Harvard UniversityOfficial
- Columbia UniversityOfficial
- Ifakara Health InstituteOfficial
- Muhimbili UniversityOfficial
- George Washington UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.